<Disease><Name>ALKAPTONURIA (AKU)</Name><Synonym>HOMOGENTISIC ACID OXIDASE DEFICIENCY</Synonym><OMIM><Number>203500</Number><URL>http://omim.org/entry/203500</URL></OMIM><Orphanet><Number>56</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=56</URL></Orphanet><Protein><Number>Homogentisate 1,2-dioxygenase</Number><URL>http://www.uniprot.org/uniprot/Q93099</URL></Protein><ExPASy><Number>1.13.11.5</Number><URL>http://enzyme.expasy.org/EC/1.13.11.5</URL></ExPASy><Gene>3q13.33</Gene><ICD>E70.2</ICD><Summary>rare (1:100000 - 1:1000000, 1:19000 in Slovakia) ;autosomal recessive;mutation in the homogentisate 1,2-dioxygenase gene;brown or dark colored urine was not observed in all patients; multi-system involvement with ochronotic arthropathy</Summary><Symptoms><symtomp><id>2350</id><symptom>aortic valvular disease</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2383</id><symptom>arthralgia</symptom><category>GENERAL TOPICS | SKELETAL DEFECT</category></symtomp><symtomp><id>2129</id><symptom>arthritis</symptom><category>SKELATAL DEFECT | SKELETAL DEFECT</category></symtomp><symtomp><id>2316</id><symptom>brown or dark colored urine</symptom><category>GENERAL TOPICS | GENITOURINARY TRACT</category></symtomp><symtomp><id>3158</id><symptom>cardiac involvement, defects or anomalies</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2449</id><symptom>heart involvement</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2026</id><symptom>hemolysis</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM | LABORATORY FINDINGS</category></symtomp><symtomp><id>3395</id><symptom>methemoglobinemia</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>3462</id><symptom>ochronosis</symptom><category>SKIN</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2089</id><symptom>Organic acids, urine</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>3962</id><symptom>osteopenia</symptom><category>SKELETAL DEFECT</category></symtomp><symtomp><id>2358</id><symptom>pain, bones or joints / pain bones</symptom><category>GENERAL TOPICS | SKELATAL DEFECT | SKELETAL DEFECT</category></symtomp><symtomp><id>2268</id><symptom>pigmentation, skin and sclera</symptom><category>SKIN</category></symtomp><symtomp><id>2395</id><symptom>skin, pigmentation</symptom><category>SKIN</category></symtomp><symtomp><id>3998</id><symptom>urine color, abnormal</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>2236</id><symptom>urolithiasis, nephrolithiasis, kidney stones</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>3461</id><symptom>uveitis</symptom><category>EYES</category></symtomp><symtomp><id>2447</id><symptom>vertebral changes or anomalies</symptom><category>BODY | SKELATAL DEFECT</category></symtomp><symtomp><id>2248</id><symptom>X-ray, abnormalities</symptom><category>LABORATORY FINDINGS</category></symtomp></Symptoms><Metabolites><metabolite><id>1623</id><name>Homogentisic acid</name><specimen>urine</specimen><value>increased</value><min>0.55</min><max>2.80</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1656</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>4.10</min><max>23.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1969</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>normal/inc</value><min>34.00</min><max>112.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1970</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>normal/inc</value><min>19.00</min><max>119.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1971</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>normal/inc</value><min>35.00</min><max>107.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite><metabolite><id>1201</id><name>Ferric chloride reaction</name><specimen>urine</specimen><value /><min>    </min><max>    </max><unit>negative</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>73</id><name>Homogentisic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>1.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1370</id><name>Homogentisic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>0.00</max><unit>not detectable</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>2021</id><name>Homogentisic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>0.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>Bruker 2018</comment></metabolite><metabolite><id>988</id><name>Homogentisic acid oxidase</name><specimen>liver</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1924</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>2.00</min><max>23.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1763</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>0.00</min><max>43.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>155</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>6.00</min><max>55.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>870</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>9.00</min><max>48.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1553</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>6.00</min><max>26.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1517</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>11.00</min><max>54.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>53</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>normal/inc</value><min>38.00</min><max>147.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>1298</id><name>L-Tyrosine</name><specimen>blood</specimen><value>normal/inc</value><min>29.06</min><max>178.41</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1299</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>normal/inc</value><min>14.00</min><max>115.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite></Metabolites><Literatures><literature><id>7321</id><title>Presentation of 14 alkaptonuria patients from Turkey</title><author>Akbaba AI,</author><journal>J Pediatr Endocrinol Metab</journal><year>2020</year><book /><volume>33</volume><number>2</number><pages>289-294</pages><co_aut>Ozguel RK, Dursun A</co_aut></literature><literature><id>8046</id><title>A Patient Survey on the Impact of Alkaptonuria Symptoms as Perceived by the Patients and Their Experiences of Receiving Diagnos</title><author>Rudebeck M,</author><journal>JIMD Rep</journal><year>2020</year><book /><volume>53</volume><number>1</number><pages>71-79</pages><co_aut>et al.</co_aut></literature><literature><id>8048</id><title>Alkaptonuric Ochronosis of the Carotid Artery</title><author>Shah A,</author><journal>SAGE Open Med Case Rep</journal><year>2020</year><book /><volume>8</volume><number>0</number><pages /><co_aut>Son A, Salehi P</co_aut></literature><literature><id>8230</id><title>Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-labe</title><author>Ranganath LR,</author><journal>Lancet Diabetes Endocrinol</journal><year>2020</year><book /><volume>8</volume><number>9</number><pages>762-772</pages><co_aut>et al.</co_aut></literature><literature><id>6960</id><title>Efficacy of low dose nitisinone in the management of alkaptonuria</title><author>Sloboda N,</author><journal>Mol Genet Metab</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6961</id><title>Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry </title><author>Curtis SL,</author><journal>Clin Biochem</journal><year>2019</year><book /><volume>71</volume><number>0</number><pages>24-30</pages><co_aut>et al.</co_aut></literature><literature><id>6962</id><title>Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria</title><author>Milan AM,</author><journal>Sci Rep</journal><year>2019</year><book /><volume>9</volume><number>1</number><pages>10024</pages><co_aut>et al.</co_aut></literature><literature><id>6963</id><title>Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS</title><author>Davison AS,</author><journal>JIMD Rep</journal><year>2019</year><book /><volume>48</volume><number>1</number><pages>67-74</pages><co_aut>et al.</co_aut></literature><literature><id>6964</id><title>Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria</title><author>Bernardini G,</author><journal>J Cell Physiol</journal><year>2019</year><book /><volume>234</volume><number>5</number><pages>6696-6708</pages><co_aut>et al.</co_aut></literature><literature><id>6965</id><title>A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria</title><author>Norman BP,</author><journal>Clin Chem</journal><year>2019</year><book /><volume>65</volume><number>4</number><pages>530-539</pages><co_aut>et al.</co_aut></literature><literature><id>7189</id><title>Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alka</title><author>Ranganath LR,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7191</id><title>Dietary restriction of tyrosine and phenylalanine lowers tyrosinaemia associated with nitisinone therapy of alkaptonuria</title><author>Hughes JH,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6966</id><title>A new integrated and interactive tool applicable to inborn errors of metabolism: Application to alkaptonuria</title><author>Spiga O,</author><journal>Comput Biol Med</journal><year>2018</year><book /><volume>103</volume><number>0</number><pages>1-7</pages><co_aut>et al.</co_aut></literature><literature><id>6967</id><title>Musculoskeletal manifestations of alkaptonuria: A case report and literature review</title><author>Wu K,</author><journal>Eur J Rheumatol</journal><year>2018</year><book /><volume>6</volume><number>2</number><pages>98-101</pages><co_aut>et al.</co_aut></literature><literature><id>6968</id><title>Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone</title><author>Griffin R,</author><journal>Data Brief</journal><year>2018</year><book /><volume>20</volume><number>0</number><pages>1620-1628</pages><co_aut>et al.</co_aut></literature><literature><id>6969</id><title>Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the </title><author>Ranganath LR,</author><journal>Mol Genet Metab</journal><year>2018</year><book /><volume>125</volume><number>1</number><pages>127-134</pages><co_aut>et al.</co_aut></literature><literature><id>6970</id><title>Alkaptonuria: A Case Report With Diagnostic Challenge</title><author>Gali VL,</author><journal>S D Med</journal><year>2017</year><book /><volume>70</volume><number>8</number><pages>366-368</pages><co_aut>et al.</co_aut></literature><literature><id>6971</id><title>A new light on Alkaptonuria: A Fourier-transform infrared microscopy (FTIRM) and low energy X-ray fluorescence (LEXRF) microsco</title><author>Mitri E,</author><journal>Biochim Biophys Acta Gen Subj</journal><year>2017</year><book /><volume>1861</volume><number>5</number><pages>1000-1008</pages><co_aut>et al.</co_aut></literature><literature><id>6972</id><title>Quick Diagnosis of Alkaptonuria by Homogentisic Acid Determination in Urine Paper Spots</title><author>Jacomelli G,</author><journal>JIMD Rep</journal><year>2017</year><book /><volume>31</volume><number>0</number><pages>51-56</pages><co_aut>et al.</co_aut></literature><literature><id>3245</id><title>Acute fatal metabolic complications in alkaptonuria</title><author>Davison AS,</author><journal>J Inherit Metab Dis</journal><year>2016</year><book /><volume>39</volume><number>2</number><pages>203-210</pages><co_aut>et al.</co_aut></literature><literature><id>3246</id><title>Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tan</title><author>Hughes AT,</author><journal>Ann Clin Biochem</journal><year>2015</year><book /><volume>52</volume><number>5</number><pages>597-605</pages><co_aut>et al.</co_aut></literature><literature><id>3247</id><title>Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria</title><author>Arnoux JB,</author><journal>J Inherit Metab Dis</journal><year>2015</year><book /><volume>38</volume><number>5</number><pages>791-796</pages><co_aut>et al.</co_aut></literature><literature><id>3248</id><title>Detection of alkaptonuria in a 1-week-old infant</title><author>Thalagahage KN,</author><journal>BMJ Case Rep</journal><year>2015</year><book /><volume>2015</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>3156</id><title>Cerebro-spinal and renal ochronosis: A rare case report</title><author>Nanda SK,</author><journal>Indian J Clin Biochem</journal><year>2010</year><book /><volume>25</volume><number>2</number><pages /><co_aut>et al.</co_aut></literature><literature><id>2873</id><title>Osteoarthritis? Ochronotic arthritis! A case study and review of the literature</title><author>Zhao BH</author><journal>Knee Surg Sports Traumatol Arthrosc</journal><year>2009</year><book /><volume>17</volume><number>7</number><pages>778-781</pages><co_aut>et al.</co_aut></literature><literature><id>2874</id><title>[Ochronosis--a rare cause of secondary gonarthrosis]</title><author>Baier C</author><journal>Z Orthop Unfall</journal><year>2009</year><book /><volume>147</volume><number>3</number><pages>366-368</pages><co_aut>et al.</co_aut></literature><literature><id>2875</id><title>Acute anterior uveitis as the initial presentation of alkaptonuria</title><author>John SS</author><journal>J Postgrad Med</journal><year>2009</year><book /><volume>55</volume><number>1</number><pages>35-37</pages><co_aut>et al.</co_aut></literature><literature><id>2876</id><title>Alkaptonuria diagnosed in a 4-month-old baby girl: a case report</title><author>Datta AK</author><journal>Cases J</journal><year>2008</year><book /><volume>13</volume><number>1</number><pages>308</pages><co_aut>et al.</co_aut></literature><literature><id>1420</id><title>Ochronotic arthropathy</title><author>Toth K</author><journal>Scand J Rheumatol</journal><year>2003</year><book /><volume>32</volume><number>5</number><pages>315-317</pages><co_aut>et al.</co_aut></literature><literature><id>1421</id><title>Urinary homogentisic acid in alkaptonuric and healthy children</title><author>Olah AV,</author><journal>Clin Chem Lab Med</journal><year>2003</year><book /><volume>41</volume><number>3</number><pages>356-359</pages><co_aut>et al.</co_aut></literature><literature><id>1422</id><title>Alkaptonuria</title><author>Lorenzini S</author><journal>N Engl J Med</journal><year>2003</year><book /><volume>348</volume><number>14</number><pages>1408</pages><co_aut>Mannoni A, Selvi E</co_aut></literature><literature><id>1423</id><title>Reversal of clinical symptoms and radiographic abnormalities with protein restriction and ascorbic acid in alkaptonuria</title><author>Morava E</author><journal>Ann Clin Biochem</journal><year>2003</year><book /><volume>40</volume><number>0</number><pages>108-111</pages><co_aut>et al.</co_aut></literature><literature><id>1603</id><title>Alkaptonuric ochronosis: a case with multiple joint replacement arthroplasties</title><author>Demir S</author><journal>Clin Rheumatol</journal><year>2003</year><book /><volume>22</volume><number>6</number><pages>437-439</pages><co_aut /></literature><literature><id>1604</id><title>Alkaptonuria: a rare metabolic disorder. A report of two cases in siblings</title><author>Matuszewska E</author><journal>Pol Merkuriusz Lek</journal><year>2003</year><book /><volume>14</volume><number>83</number><pages>444-446</pages><co_aut>et al.</co_aut></literature><literature><id>1605</id><title>Spontaneous tendon ruptures in alkaptonuria</title><author>Manoj Kumar RV</author><journal>J Bone Joint Surg Br</journal><year>2003</year><book /><volume>85</volume><number>6</number><pages>883-886</pages><co_aut>Rajasekaran S</co_aut></literature><literature><id>1606</id><title>Molecular analyses of the HGO gene mutations in Turkish alkaptonuria patients suggest that the R58fs mutation originated from c</title><author>Uyguner O</author><journal>J Inherit Metab Dis</journal><year>2003</year><book /><volume>26</volume><number>1</number><pages>17-23</pages><co_aut>et al.</co_aut></literature><literature><id>1607</id><title>Alkaptonuria caused by compound heterozygote mutations</title><author>Elcioglu NH</author><journal>Genet Couns</journal><year>2003</year><book /><volume>14</volume><number>2</number><pages>207-213</pages><co_aut>et al.</co_aut></literature><literature><id>1207</id><title>Natural history of alkaptonuria</title><author>Phornphutkul C</author><journal>N Engl J Med</journal><year>2002</year><book /><volume>347</volume><number>0</number><pages>2111-2121</pages><co_aut>et al.</co_aut></literature><literature><id>1208</id><title>Ocular ochronosis in alkaptonuria patients carrying mutations in the homogentisate 1,2-dioxygenase gene</title><author>Felbora U</author><journal>Br J Ophthalmol</journal><year>1999</year><book /><volume>83</volume><number>0</number><pages>680-683</pages><co_aut>et al.</co_aut></literature><literature><id>175</id><title>Alkaptonuria</title><author>La Du BN</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>1</volume><number>39</number><pages>1371-1386</pages><co_aut /></literature><literature><id>6973</id><title>Alkaptonuria</title><author>Introne WJ,</author><journal>GeneReviews&#174; [Internet]</journal><year>0</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Gahl WA</co_aut></literature></Literatures></Disease>